MX2021002289A - Proteinas quimericas basadas en flt3l. - Google Patents

Proteinas quimericas basadas en flt3l.

Info

Publication number
MX2021002289A
MX2021002289A MX2021002289A MX2021002289A MX2021002289A MX 2021002289 A MX2021002289 A MX 2021002289A MX 2021002289 A MX2021002289 A MX 2021002289A MX 2021002289 A MX2021002289 A MX 2021002289A MX 2021002289 A MX2021002289 A MX 2021002289A
Authority
MX
Mexico
Prior art keywords
flt3l
chimeric proteins
based chimeric
extracellular domain
fms
Prior art date
Application number
MX2021002289A
Other languages
English (en)
Inventor
George Fromm
Taylor Schreiber
Silva Suresh De
Original Assignee
Shattuck Labs Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shattuck Labs Inc filed Critical Shattuck Labs Inc
Publication of MX2021002289A publication Critical patent/MX2021002289A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere, entre otros, a composiciones y métodos, que incluyen proteínas quiméricas que comprenden un dominio extracelular de ligando de tirosina cinasa 3 tipo FMS (FLT3L) y un dominio extracelular de una proteína transmembrana de tipo II que pueden utilizarse en el tratamiento de una enfermedad, tal como el cáncer.
MX2021002289A 2018-08-29 2019-08-29 Proteinas quimericas basadas en flt3l. MX2021002289A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862724596P 2018-08-29 2018-08-29
PCT/US2019/048922 WO2020047327A2 (en) 2018-08-29 2019-08-29 Flt3l-based chimeric proteins

Publications (1)

Publication Number Publication Date
MX2021002289A true MX2021002289A (es) 2021-05-27

Family

ID=69643788

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021002289A MX2021002289A (es) 2018-08-29 2019-08-29 Proteinas quimericas basadas en flt3l.

Country Status (9)

Country Link
US (1) US20240122983A1 (es)
EP (1) EP3843755A4 (es)
JP (1) JP2022512540A (es)
CN (1) CN112888711A (es)
AU (1) AU2019333175A1 (es)
CA (1) CA3109352A1 (es)
IL (1) IL281088A (es)
MX (1) MX2021002289A (es)
WO (1) WO2020047327A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220032568A (ko) * 2019-06-25 2022-03-15 길리애드 사이언시즈, 인코포레이티드 Flt3l-fc 융합 단백질 및 사용 방법
JP2023506501A (ja) * 2019-12-16 2023-02-16 ワシントン・ユニバーシティ キメラ抗原受容体樹状細胞（ｃａｒ－ｄｃ）ならびにこれを作製および使用する方法
WO2022089418A1 (zh) * 2020-10-26 2022-05-05 信达生物制药(苏州)有限公司 重组截短FLT3配体与人抗体Fc的融合蛋白

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK782002A3 (en) * 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
CA2407336A1 (en) * 2000-04-25 2001-11-01 Immunex Corporation Method for treatment of tumors using photodynamic therapy
MXPA03003632A (es) * 2000-10-24 2003-09-10 Immunex Corp Metodo para tratamiento de tumores usando terapia de combinacion.
CN101198621A (zh) * 2005-01-25 2008-06-11 阿波罗生命科学有限公司 分子及其嵌合分子
US20140079704A1 (en) * 2012-09-11 2014-03-20 The Texas A&M University System BI-Specific Diabodies For Masking And Targeting Vaccines
US10183060B2 (en) * 2015-10-01 2019-01-22 Heat Biologics, Inc. Compositions and methods for adjoining type I and type II extracellular domains as heterologous chimeric proteins
KR101860233B1 (ko) * 2015-12-08 2018-05-21 연세대학교 산학협력단 ＧＭ－ＣＳＦ 유전자；Ｆｌｔ３Ｌ－ＴＲＡＩＬ 융합 유전자；ＴＧＦ－β 발현을 억제하는 ｓｈＲＮＡ； 및 ＨＳＰ 발현을 억제하는 ｓｈＲＮＡ를 포함하는 항종양 조성물

Also Published As

Publication number Publication date
EP3843755A2 (en) 2021-07-07
EP3843755A4 (en) 2022-08-31
WO2020047327A3 (en) 2020-07-23
CA3109352A1 (en) 2020-03-05
JP2022512540A (ja) 2022-02-07
US20240122983A1 (en) 2024-04-18
IL281088A (en) 2021-04-29
WO2020047327A2 (en) 2020-03-05
AU2019333175A1 (en) 2021-03-04
CN112888711A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
MX2022001299A (es) Composiciones y métodos para unir dominios extracelulares de tipo i y tipo ii como proteínas quiméricas heterólogas.
PH12019501533A1 (en) Tigit-and light-based chimeric proteins
NZ739499A (en) Single domain antibody for programmed death-ligand (pd-l1) and derived protein thereof
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
MX2021002289A (es) Proteinas quimericas basadas en flt3l.
MX2020014031A (es) Proteinas heterodimericas y usos de las mismas.
PH12020551019A1 (en) IL-22 Fc FUSION PROTEINS AND METHODS OF USE
PH12019501534A1 (en) Csf1r-based chimeric proteins
PH12021551500A1 (en) Anti-ctla4 antibodies and methods of use thereof
MY190625A (en) Anti-vegf protein compositions and methods for producing the same
MX2020007628A (es) Composiciones y metodos de uso.
MX2021007589A (es) Anticuerpos anti il-36 y procedimientos de uso de estos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
NZ762312A (en) Anti-pacap antibody
EP4249503A3 (en) Vsig8-based chimeric proteins
MX2021002292A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en sirp alfa.
MX2021002286A (es) Terapias de combinacion.
WO2020102243A3 (en) In-flow photooxygenation of aminothienopyridinones generates novel ptp4a3 phosphatase inhibitors
EP3946409A4 (en) CHEMICAL PROTEINS BASED ON FMS-LIKE TYROSINE KINASE-3 LIGAND (FLT3L)
MX2021002291A (es) Terapias de combinacion que comprenden proteinas quimericas basadas en tim-3.
PL427190A1 (pl) Fosfoorganiczne pochodne peptydowe będące analogami N-końcowej sekwencji białka Smac, sposób ich wytwarzania oraz ich zastosowanie